Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NewAmsterdam Pharma Company N.V. - Warrant (NQ:NAMSW)

25.20 -2.10 (-7.69%)
Streaming Delayed Price Updated: 1:26 PM EST, Dec 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NewAmsterdam Pharma Company N.V. - Warrant

< Previous 1 2 3 Next >
News headline image
NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
From NewAmsterdam Pharma N.V
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From NewAmsterdam Pharma N.V
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors
From NewAmsterdam Pharma N.V
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Announces 2024 Strategic Priorities
From NewAmsterdam Pharma N.V
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights
From NewAmsterdam Pharma N.V
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer
From NewAmsterdam Pharma N.V
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer’s Disease Who Carry an ApoE4 Mutation
From NewAmsterdam Pharma N.V
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference
From NewAmsterdam Pharma N.V
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular Disease
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary Shares
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Announces Pricing of Upsized Secondary Offering of Ordinary Shares
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Announces Commencement of Secondary Offering of Ordinary Shares
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Announces Positive Topline Results from Phase 2b Dose-Finding Trial Evaluating Obicetrapib in Japanese Patients
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Present at Jefferies Healthcare Conference
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
News headline image
NewAmsterdam to Present Full Data from ROSE2 at NLA Scientific Sessions 2023
NewAmsterdam to review data on webcast conference call on June 5, 2023 at 8:00 a.m. ET 
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Highlights
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Appoints Janneke van der Kamp to its Board of Directors
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Reports Full Year 2022 Financial Results and Provides Corporate Update
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Present at Cowen 43rd Annual Health Care Conference
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Present at the SVB Securities Global BioPharma Conference
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Appoints John W. Smither to its Board of Directors
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
News headline image
NewAmsterdam Announces Positive Results from ROSE2, Phase 2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
News headline image
NewAmsterdam Announces Appointment of David Topper as Chief Financial Officer
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.